Sirona Biochem Corp. Management Team Restructuring: Mark Senner Appointed to President, Christopher Hopton to Chief

VANCOUVER, BC, Apr 29 (MARKET WIRE) --
Dr. Howard Verrico reports:

Sirona Biochem Corp. (TSX-V: SBM), formerly High Rider Capital Inc., has
restructured the management team with the appointments of Mark Senner as
President and Director, Christopher Hopton, CGA, as Chief Financial
Officer and John Dougherty to Corporate Development. Dr. Howard Verrico
will remain as Chief Executive Officer, Director and will become Corporate
Secretary.

Mr. Senner brings 24 years of experience spanning key positions to support
the sales and marketing of commercialized pharmaceutical products with
major pharmaceutical companies in Canada. Mr. Senner joined SBC (August
2008) in the role of Senior Project Manager and spearheaded the overall
effort to achieve significant milestones culminating in the final
approvals for the company's Qualifying Transaction and subsequent active
trading to commence May 4, 2009. Mr. Senner has led the team through the
licensing agreement with TFChem, coordination of the scientific research
plan, approval of the Prospectus and Qualifying Transaction and most
recent Private Placement. Mr. Senner's experience, business acumen and
knowledge of the pharmaceutical industry will be instrumental for SBC
future success.

"As a physician dealing with the day to day challenges associated with
Diabetes and Obesity, it is with great enthusiasm to share this project
with Mark. He brings the necessary experience to lead this exciting new
drug discovery program. Mark shares my vision of the enormous potential of
our SGLT drug development program," said Dr. Verrico.

SBC has appointed Mr. Christopher D. Hopton C.G.A. as Chief Financial
Officer. Mr. Hopton has over 14 years of accounting experience working
with private and public companies. Mr. Hopton is a hands-on,
team-oriented, professional accountant with a degree in Business
Administration. Currently, Mr. Hopton is CFO with Central Resources Corp.
In addition to his public company experience, Mr. Hopton has over 20
active clients in the private sector. Mr. Hopton was formerly Division
Controller for Canadian Airlines as well as part of the core
restructuring team for 360 Networks and had a significant role in the
buyout by Bell Canada.

"We are pleased to complete our team by retaining someone of such high
caliber as Christopher. He will manage the financial health of Sirona
Biochem to enable us to meet our important future milestones.
Christopher's extensive knowledge in finance and accounting will
contribute a wealth of experience to the Company's management team and
the overall success of the project," said Dr. Howard Verrico.

The Board of Directors has accepted the resignation of Mr. Roger MacInnis
as CFO, Secretary and Director to allow his pursuit of other interests.
The Company wishes to thank Mr. Roger MacInnis for his services and
overall contributions to Sirona Biochem Corp. since the inception of the
company.

John Dougherty joins the team in the role of Corporate Development &
Investor Relations. Mr. Dougherty has over 30 years of experience as an
investment advisor and broker in addition to a great deal of experience
related to restructuring and developing businesses in the public sector.

Dr. Howard Verrico,
Chief Executive Officer

About: Mr. Mark Senner

Mark Senner is a Senior Business Leader with over 24 years of experience
in sales, sales and marketing management, sales operations, project
management, and key account management of commercialized pharmaceuticals.
Mark has built and strengthened his skills and expertise through a variety
of positions both regionally and nationally at Merck-Frosst Canada Inc.,
Bristol-Myers Squibb Canada Inc., Solvay Canada, Novartis Canada Inc. and,
Biovail Pharmaceuticals Canada.

Through Mark's creative and critical analysis of complex challenges and
opportunities he consistently exceeded sales and overall performance
measures every year through a focused, results-oriented approach. Mark
achieved his goals in working through highly motivated teams that took
pride in delivering organizational goals. Mark has extensive experience in
leading and working through others to consistently achieve superior and
positive outcomes, with particular strengths and interests in coaching,
leadership, project analysis and management, teambuilding, staffing
effectiveness and organizational development.

Mark enjoys a challenge, has a passion for excellence and rises to being
responsible and accountable for tasks and projects with productive and
meaningful outcomes. His greatest strength is having an eye for talent,
surrounding himself with positive and dynamic people, attracting highly
skilled, proactive, motivated, able and stable employees to build dynamic
and productive sales and project teams to deliver superior results and
contribute to the success of any organization or company. Mark is highly
motivated, excited and very interested in applying his extensive
experience to SBC. Mark makes valuable contributions in any organization
through his experience, leadership and critical business analysis and
creative results-oriented thinking.

Mark holds a BSc. from the University of British Columbia with additional
certifications in sales and marketing leadership and management.

About: Mr. Christopher Hopton

Mr. Christopher Hopton is Professional Accountant with over with over 14
years of experience in all aspects of Financial Planning, Accounting
Policy implementation and Business Process Improvement. He established
Orcas Island Finance Ltd. in 1994, a business investment and consulting
company with over 20 active clients in privately held and publicly traded
companies. Most recently he has assumed the role of CFO for Central
Resources Corp. a junior mineral exploration company that went public in
September 08. Formerly he held the position of Division Controller for
Canadian Airlines where he was responsible for an annual operating budget
of $200M. He gained valuable experience as part of the team restructuring
360networks Inc. The conclusion of the 360networks restructuring resulted
in a successful buy-out by Bell Canada.

Christopher has earned a Bachelor of Business Administration from Simon
Fraser University and is a Certified Professional Accountant (CGA).

About the Company:

Sirona Biochem Corp. (SBC) is an emerging biotech company dedicated to the
discovery and development of novel drug compounds. The current focus is
on treatments for Type II Diabetes and Obesity. SBC has entered into a
license agreement with TFChem S.A.R.L., a Drug Discovery company based in
Rouen, France. TFChem licenses its technology of fluorinated carbohydrate
mimics: GlycoMim(R), and products in development to biotech companies. The
license agreement with TFChem provides for research and development of new
compounds known as S.G.L.T. inhibitors. S.G.L.T. inhibitors are a new and
exciting class of compounds which have great promise and potential to
treat both diabetes and obesity.

For further information, please contact
Mr. John Dougherty
Corporate Development
(604) 641-4466
toll free: 1-888-SIRONA1 (747-6621)
email info@sironabiochem.com

Copyright 2009, Market Wire, All rights reserved.

-0-